BHC Stock Summary and Trading Ideas (Bausch Health Companies | NYSE:BHC)

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

Bausch Health Companies trades on the NYSE stock market under the symbol BHC.

As of May 15, 2026, BHC stock price declined to $5.42 with 964,385 million shares trading.

BHC has a beta of 1.48, meaning it tends to be more sensitive to market movements. BHC has a correlation of 0.09 to the broad based SPY ETF.

BHC has a market cap of $2.01 billion. This is considered a Mid Cap stock.

Last quarter Bausch Health Companies reported $3 billion in Revenue and $.78 earnings per share. This beat revenue expectation by $116 million and exceeded earnings estimates by $.06.

In the last 3 years, BHC traded as high as $11.46 and as low as $3.96.

The top ETF exchange traded funds that BHC belongs to (by Net Assets): DFIS, DISV, PPH, DFIC, DFAX.

BHC has underperformed the market in the last year with a price return of +17.8% while the SPY ETF gained +26.4%. BHC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.5% and -4.1%, respectively, while the SPY returned +8.7% and +2.6%, respectively.

BHC support price is $5.28 and resistance is $5.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHC shares will trade within this expected range on the day.